Babaodan Capsules for viral hepatitis: systematic review of clinical efficacy and safety and Meta-analysis of randomized clinical trials.
10.19540/j.cnki.cjcmm.20190627.501
- Author:
Hao-Xin YANG
1
;
Jin GOU
2
;
Po HUANG
3
;
Yan-Yan DAI
4
;
Xiu-Wen ZHANG
4
;
Yu XIN
4
;
Guo-Zhen ZHAO
5
;
Bo LI
3
Author Information
1. Beijing Hospital of Traditional Chinese Medicine,Capital Medical University Beijing 100010,China Beijing University of Chinese Medicine Beijing 100029,China.
2. Dongfang Hospital,Beijing University of Chinese Medicine Beijing 100078,China.
3. Beijing Hospital of Traditional Chinese Medicine,Capital Medical University Beijing 100010,China Beijing Institute of Traditional Chinese Medicine Beijing 100010,China.
4. Dongzhimen Hospital,Beijing University of Chinese Medicine Beijing 100700,China.
5. Beijing Hospital of Traditional Chinese Medicine,Capital Medical University Beijing 100010,China.
- Publication Type:Systematic Review
- Keywords:
Babaodan Capsules;
Meta-analysis;
systematic review;
viral hepatitis
- MeSH:
Antiviral Agents/therapeutic use*;
Capsules;
Drugs, Chinese Herbal/therapeutic use*;
Hepatitis/drug therapy*;
Humans;
Male;
Randomized Controlled Trials as Topic;
Treatment Outcome
- From:
China Journal of Chinese Materia Medica
2019;44(22):4953-4961
- CountryChina
- Language:Chinese
-
Abstract:
To systemically analyze the efficacy and safety of Babaodan Capsules in treatment of viral hepatitis. Databases such as CNKI,Wan Fang Date,VIP,Sino Med,PubMed,and Cochrane Library were electronically searched for relevant randomized controlled trials about Babaodan Capsules in the treatment of viral hepatitis,from database establishment to November 11,2018. Two researchers independently screened the literature and extracted data according to the inclusion criteria. GRADE system was used to evaluate evidence quality,and we used the Cochrane Rev Man 5. 3 software for Meta-analysis. Six randomized controlled trials including 520 subjects were included. Babaodan Capsules combined with conventional treatment were used as intervention measures,and the conventional treatment was used as the control measures. The results showed Babaodan Capsules combined with conventional treatment had better efficacy on reducing the total bilirubin( MD =-16. 25,95% CI[-19. 86,-12. 63]),alanine aminotransferase( MD =-26. 62,95% CI[-41. 18,-12. 06]),total bile acid( MD=-46. 02,95%CI[-49. 18,-42. 85]) and improving clinical efficiency( RR = 1. 34,95%CI[1. 13,1. 59]) than conventional treatment alone. In addition,Babaodan Capsules combined with conventional treatment can delay the progression of liver fibrosis to some extent. Qualitative analysis showed that the combined treatment regimen was more effective in relieving clinical symptoms. There was no significant difference between the two regimens in increasing albumin and prothrombin activity. Babaodan Capsules combined with conventional treatment showed no adverse reactions. In summary,for patients with viral hepatitis,the combination of Babaodan Capsules and conventional treatment has more advantages in reducing total bilirubin,alanine aminotransferase and total bile acid and is more effective in improving clinical symptoms as compared with conventional Western medicine,with no serious adverse reactions. Its clinical application with syndrome differentiation method can be considered. However,due to the limited number and quality of the original researches,more multi-center,high-quality randomized controlled trials are needed for further verification.
